[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,656,763
  • Shares Outstanding, K 125,083
  • Annual Sales, $ 376,070 K
  • Annual Income, $ -16,140 K
  • EBIT $ 3 M
  • EBITDA $ 6 M
  • 60-Month Beta 1.58
  • Price/Sales 7.04
  • Price/Cash Flow N/A
  • Price/Book 13.62

Options Overview Details

View History
  • Implied Volatility 53.41% (-16.60%)
  • Historical Volatility 64.97%
  • IV Percentile 2%
  • IV Rank 2.88%
  • IV High 139.00% on 03/18/26
  • IV Low 50.87% on 12/30/25
  • Expected Move (DTE 3) 1.27 (5.96%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 156
  • Volume Avg (30-Day) 197
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 9,603
  • Open Int (30-Day) 7,550
  • Expected Range 19.97 to 22.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.04
  • Number of Estimates 3
  • High Estimate $0.09
  • Low Estimate $0.00
  • Prior Year $-0.13
  • Growth Rate Est. (year over year) +130.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.19 +5.20%
on 05/07/26
25.47 -16.61%
on 04/14/26
-2.97 (-12.27%)
since 04/10/26
3-Month
20.19 +5.20%
on 05/07/26
28.80 -26.25%
on 02/26/26
-5.35 (-20.12%)
since 02/11/26
52-Week
12.72 +66.98%
on 06/13/25
31.77 -33.14%
on 12/08/25
+7.71 (+56.98%)
since 05/09/25

Most Recent Stories

More News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 21.24 (+0.33%)
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

Q1 2026 net product revenue for ZORYVE ® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025 Continued strong demand for ZORYVE despite typical...

ARQT : 21.24 (+0.33%)
Arcutis Reports Tomorrow Having Already Told Investors Exactly What Growth to Expect

Barchart Research What to Expect from ARQT Earnings ARQT Generated May 5, 2026 Current Price $23.42 EPS Estimate $$-0.02 Consensus Rating Moderate Buy Average Move 7.56% Arcutis Reports Tomorrow Having...

ARQT : 21.24 (+0.33%)
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis Once-daily ZORYVE cream was well tolerated...

ARQT : 21.24 (+0.33%)
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitor...

ARQT : 21.24 (+0.33%)
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 21.24 (+0.33%)
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S. sales...

INCY : 100.32 (+1.79%)
ARQT : 21.24 (+0.33%)
PVLA : 122.09 (+0.66%)
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference

WESTLAKE VILLAGE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 21.24 (+0.33%)
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms...

ARQT : 21.24 (+0.33%)
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful...

ARQT : 21.24 (+0.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis,...

See More

Key Turning Points

3rd Resistance Point 22.44
2nd Resistance Point 22.08
1st Resistance Point 21.66
Last Price 21.24
1st Support Level 20.88
2nd Support Level 20.52
3rd Support Level 20.10

See More

52-Week High 31.77
Fibonacci 61.8% 24.49
Fibonacci 50% 22.25
Last Price 21.24
Fibonacci 38.2% 20.00
52-Week Low 12.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.